# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE

A. 510(k) Number: k050976   
B. Purpose for Submission: To include Trimethoprim/sulfamethoxazole on the ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ gram positive AST panel for testing appropriate gram positive isolates.   
C. Measurand: Trimethoprim/sulfamethoxazole at $\underline { { < 0 . 5 / 9 . 5 } } - \underline { { > } } 1 6 / 3 0 4 \mu \mathrm { g / m l }$   
D. Type of Test: Qualitative growth based detection algorithm using optics light detection   
E. Applicant: bioMerieux, Inc.   
F. Proprietary and Established Names: VITEK $^ { \circledast } 2$ Gram Positive Trimethoprim/sulfamethoxazole

# G. Regulatory Information:

1. Regulation section: 866.1645 Short-Term Antimicrobial Susceptibility Test System   
2. Classification: II   
3. Product Code: LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation   
4. Panel: 83 Microbiology

# H. Intended Use:

1. Intended use(s): The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.

The VITEK $^ { \textregistered } 2$ Gram Positive susceptibility Card is intended for use with the VITEK $^ { \textregistered } 2$ System and the VITEK® 2 Compact System in clinical laboratories as an in vitro test to determine the susceptibility of Staphylococcus spp., Enterococcus spp., and Streptococcus agalactiae to antimicrobial agents when used as instructed in the Online Product Information.

# 2. Indication(s) for use:

This submission is for the addition of the antibiotic Trimethoprim/sulfamethoxazole at concentrations at 2, 8, and $1 6 ~ \mathrm { u g / m L }$ for a calling range of $\leq 0 . 5 / 9 . 5 - \geq 1 6 / 3 0 4 \mathrm { u g / m L }$ to the ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ gram positive susceptibility CARD for the testing of Staphylococcus aureus.

It is intended for use with the $\mathrm { { V I T E K } } ^ { \textregistered } 2$ and VITEK $^ { \mathfrak { P } } 2$ Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.

3. Special condition for use statement(s): Prescription Use only.

4. Special instrument Requirements: Not applicable

# I. Device Description:

Each VITEK ${ \mathfrak { P } } _ { 2 }$ test card contains 64 microwells. A control well, that contains only microbiological culture medium is resident on all cards, with the remaining wells containing premeasured amounts of a specific antibiotic combined with culture medium. A suspension of organism is made in $0 . 4 5 \%$ sterile saline from a pure culture and standardized to a McFarland 0.5 standard using the DensiChek. The ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling and sealing operation. Each card is manually transferred from the cassette to a card loader to a place into a slot on a carousel where it remains throughout its incubation. The VITEK ${ \textsuperscript { ( B ) } } _ { 2 }$ systems monitor growth by optical scanning of each well in the card over a defined period of time (up to 18 hours) of incubation at $3 5 . 5 ^ { \mathrm { o } } \mathrm { C }$ . Minimum Inhibitory Concentration (MIC) readings are performed every 15 minutes. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.

# J. Substantial Equivalence Information:

1. Predicate device name(s): VITEK® 2 Gram Positive AST Panel for sparfloxacin   
2. Predicate K number(s): N50510/S141   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>AST testing of gram positiveisolates</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test organism</td><td rowspan=1 colspan=1>Colonies of Staphylococcusspp.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test Card</td><td rowspan=1 colspan=1>VITEK® 2 card format withbase broth</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>VITEK® 2 System and theVITEK® 2 Compact System</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Performance</td><td rowspan=1 colspan=1>Categorical interpretation</td><td rowspan=1 colspan=1>Categorical interpretation</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Antibiotic</td><td rowspan=1 colspan=1>Trimethoprim/sulfamethoxazole</td><td rowspan=1 colspan=1>Sparfloxacin</td></tr><tr><td rowspan=1 colspan=1>Reading algorithm</td><td rowspan=1 colspan=1>Unique forTrimethoprim/sulfamethoxazole</td><td rowspan=1 colspan=1>Unique for Sparfloxacin</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA”; Clinical and Laboratory Standards Institute (CLSI) M7 (M100-S15) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard”.

# L. Test Principle:

Optics systems use visible light to directly measure organism growth. These transmittance optics are based on an initial light reading of a well before significant growth has begun. Periodic light transmittance samplings of the same well measure organism growth by how much light is prevented from going through the well. An interpretive call is made between 4 and 16 hours for an early reading of results with an option to incubate up to 18 hours if necessary. The VITEK® 2 Susceptibility Card test is based on the microdilution minimum inhibitory concentration technique with concentrations equivalent to standard method concentrations. Several parameters based on the growth characteristics observed are used to provide appropriate input for the MIC calculations. Discriminate analysis is used to develop the algorithm that determines the susceptibility result for all antimicrobials on the ${ \mathrm { V I T E K } } ^ { \textregistered } 2$ systems. The MIC result must be linked to an organism identification in order to determine a category interpretation. A category interpretation will be reported.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

Ten on-scale S. aureus isolates were tested in triplicate at each of three sites for three days for an overall inter and intra site reproducibility of $59 5 \%$ . This testing was performed using both the manual dilution of the inoculum and also the automatic dilution method.   
b. Linearity/assay reportable range: Not applicable   
c. Traceability (controls, calibrators, or method): Quality Control was performed during the studies using both the auto-dilution and the manual method of diluting the organisms. This included one recommended QC organism with the following results.

<table><tr><td rowspan=1 colspan=1>ORGANISM</td><td rowspan=1 colspan=1>VITEK®Conc.</td><td rowspan=1 colspan=1>Auto-dilution</td><td rowspan=1 colspan=1>Manualdilution</td><td rowspan=1 colspan=1>Referenceconc.</td><td rowspan=1 colspan=1>Reference</td></tr><tr><td rowspan=8 colspan=1>S. aureus ATCC29213Range ≤0.5/9.5ug/mL</td><td rowspan=1 colspan=1>≤10</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>≤10</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>≥320</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>640</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>≥1280</td><td rowspan=1 colspan=1></td></tr></table>

Inoculum density control: Internal verification of the DensiChek was performed using 2 ATCC organisms and five instruments with 50 results available for each organism. The clinical sites also performed weekly standardization of the DensiChek used at that site. All recorded calibrated values were within acceptable parameters.

d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable   
$f .$ Assay cut-off: Not applicable

2. Comparison studies:

# a. Method comparison with predicate device:

A comparison of the clinical data was performed to the broth macrodilution as the reference method as described in the CLSI M7. All of the test organisms that provided results did so in ${ < } 1 6$ hours. Testing was performed using the automatic dilution feature. In the Clinical testing both oxacillin susceptible and oxacillin resistant Staphylococcus aureus were tested at three sites that included both clinical and challenge isolates. A total of 405 clinical isolates were tested. Due to insufficient concentrations tested, $( < 5 )$ a CA only can be determined. The data in the table below reflects the testing performed using broth macrodilution as the reference method for the evaluation criteria:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>total</td><td rowspan=1 colspan=1>CA</td><td rowspan=1 colspan=1>%CA</td><td rowspan=1 colspan=1>#R</td><td rowspan=1 colspan=1>min</td><td rowspan=1 colspan=1>maj</td><td rowspan=1 colspan=1>vmj</td></tr><tr><td rowspan=1 colspan=1>Clinical</td><td rowspan=1 colspan=1>405</td><td rowspan=1 colspan=1>403</td><td rowspan=1 colspan=1>99.5</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Challenge</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>478</td><td rowspan=1 colspan=1>99.6</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

CA-Category agreement vmj-very major discrepancies min-minor discrepancies maj-major discrepancies

CA is when the interpretation of the VITEK $^ { \textregistered } 2$ results agrees exactly with the interpretation of the reference method. The CA is acceptable when compared to the reference method as described in the FDA guidance document, “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA”.

The challenge set of organisms was also tested at one site using the manual and auto-dilution methods of inoculation with the following performance that demonstrated that there was little or no difference between the two inoculation methods. The table below contains the data from the two dilution methods of testing Staphylococcus aureus using broth macrodilution as the reference method:

Manual testing:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>total</td><td rowspan=1 colspan=1>#R</td><td rowspan=1 colspan=1>CA</td><td rowspan=1 colspan=1>%CA</td><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Maj</td><td rowspan=1 colspan=1>vmj</td></tr><tr><td rowspan=1 colspan=1>Challenge</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Autodilution testing:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>total</td><td rowspan=1 colspan=1>#R</td><td rowspan=1 colspan=1>CA</td><td rowspan=1 colspan=1>%CA</td><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Maj</td><td rowspan=1 colspan=1>vmj</td></tr><tr><td rowspan=1 colspan=1>Challenge</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

The test device had a growth rate of $59 5 \%$ .

$b$ . Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a and b are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Staphylococcus spp. <2/38 (S), >4/76 (R) The expected value range and the interpretive criteria are the same as recommended in CLSI.

Staphylococcus spp. ${ \underline { { < 0 . 5 } } } / 9 . 5$ (S) QC is the same as recommended in CLSI.

# N. Proposed Labeling

The labeling is sufficient and it satisfies the requirement of 21 CFR Part 809.10

O. Conclusion:   
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.